
2nd Dutch Antisense Therapeutics Symposium
Provisional program
DAY 1 (Thursday June 1st)
9:45 – 10:15 Registration Open
10:15 – 10:30 Welcome and official opening
10:30 – 11:15 International Keynote Lecture 1: Aurélie Goyenvalle, Univ. of Versailles, France
11:15 – 12:30 Session 1:
11:15 – 11:45 Invited Speaker 1 (Delivery)
11:45 – 12:00 Selected Abstract 1
12:00 – 12: 15 Selected Abstract 2
12:15 – 12:30 Sponsor pitches
12:30 – 13:30 Lunch
13:30 – 15:00 Session 2:
13:30 – 14:00 Monica Aguila (ProQR Therapeutics)
Title: TBA Topic: New Technologies
14:00 – 14:15 Selected Abstract 3
14:15 – 14:30 Selected Abstract 4
14:30 – 14:45 Selected Abstract 5
14:45 – 15:00 Selected Abstract 6
15:00 – 15:15 Selected Poster Pitches Session 1
15:15 – 16:30 Poster Session 1 with coffee and tea
16:30 – 18:00 Session 3:
16:30 – 17:00 Erik de Vrieze (Radboudumc)
Title: TBA Topic: Preclinical development of antisense therapies for ear-related disorders
17:00 – 17:15 Selected Abstract 7
17:15 – 17:30 Selected Abstract 8
17:30 – 17:45 Selected Abstract 9
17:45 – 18:10 Virginia Arechavala-Gomeza (Biocruces Bizkaia Health Research Institute, Spain)
Title: TBA Topic: The importance of networking
18:10 – 18:15 Closing of day 1
19:30 Networking dinner and pubquiz (not incl. in the registration costs)
9:00 – 9:45 International Keynote Lecture 2: Timothy Yu, Boston Children’s Hospital, USA
9:45 – 11:00 Session 4: Dutch Center for RNA Therapeutics (DCRT)
9:45 – 10:05 Marlen Lauffer (LUMC)
Building a framework for the identification and selection of cases for personalized ASO treatments
10:05 – 10:25 Ype Elgsma (ErasmusMC)
ASO treatment for Angelman Syndrome: Promises and threats
10:25 – 10:45 Rob Collin (Radboudumc)
Splicing modulation therapy for inherited retinal diseases: the example of Stargardt disease
10:45 – 11:00 Invited Speaker 5 (Regulatory affairs)
11:00 – 11:15 Selected Poster Pitches Session 2
11:15 – 12:30 Poster Session 2 with coffee and tea
12:30 – 13:30 Lunch
13:30 – 15:15 Session 5:
13:30 – 14:00 Nicole Datson (VICO Therapeutics)
VO659, an allele-preferential CAG repeat-targeting ASO with therapeutic potential for
patients with Huntington’s disease and spinocerebellar ataxia types 1 and 3
14:00 – 14:30 Invited Speaker 7 (Patient perspective)
14:30 – 14:45 Selected Abstract 10
14:45 – 15:00 Selected Abstract 11
15:00 – 15:15 Selected Abstract 12
15:15 – 15:25 Award ceremony
15:25 – 15:35 Closing remarks
15:35 – 17:00 Networking drinks